HLHong Li

Hong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Li has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Ge

    State Key Laboratory of Systems Medicine for Cancer Shanghai Cancer Institute Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    21 shared publications
  • Taoyang Chen

    Department of Pathology Qidong Liver Cancer Institute Qidong People's Hospital Affiliated Qidong Hospital of Nantong University Qidong Jiangsu China

    21 shared publications
  • Fangyu Zhao

    State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    20 shared publications
  • Ming Yao

    Division of Hematology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan

    19 shared publications
  • Jinjun Li

    State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    18 shared publications
  • Haiyang Xie

    Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

    15 shared publications

Latest Publications

  • Open Access

    The TUBA1B–G3BP2 Axis Sustains p65 Transcriptional Activity to Promote Hepatocellular Carcinoma Progression

    by Fen Lin, Hechun Lin, Junming Yu, Chao Ge, Lin Mao, Saihua Zhang, Yizi Jin, Yunyu Wu, Taoyang Chen, Jinjun Li, et al.

    Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, yet mechanisms sustaining malignant progression remain incompletely defined. Integrative analyses across multiple HCC cohorts identified TUBA1B as one of the most consistently upregulated tubulin isotypes whose high expression associates with poor prognosis and metastasis. In hydrodynamic tail‐vein injection (HTVi) models, co‐expression of Tuba1b with myr‐AKT enhanced liver tumor growth, supporting a tumor‐promoting role for Tuba1b in vivo. TUBA1B knockdown suppressed HCC cell proliferation, migration, and invasion in vitro and reduced tumor growth and metastasis in orthotopic models. HTVi‐mediated delivery of sg Tuba1b suppressed hepatocarcinogenesis in NRasV12/myr‐AKT – and MYC/sg‐p53 HCC models and prolonged survival in the former, whereas sg Tuba1b delivery to normal livers caused no detectable histological abnormalities. Mechanistically, TUBA1B bound and stabilized G3BP2 by restraining TRIM25‐dependent K48‐linked ubiquitination, thereby promoting G3BP2–IκBα association and sustaining basal NF‐κB/p65 transcriptional activity; enforced G3BP2 expression rescued the proliferative and metastatic defects caused by TUBA1B loss. Clinically, combined upregulation of TUBA1B and G3BP2 with elevated p65 activity delineated a high‐risk HCC subgroup with the poorest outcomes. Collectively, these findings define a TUBA1B–G3BP2 stability axis that supports malignant phenotypes and highlight a potential therapeutic vulnerability in HCC.


  • Open Access

    Data from Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma

    by Helei Hou, Hefen Sun, Ping Lu, Chao Ge, Lixing Zhang, Hong Li, Fangyu Zhao, Hua Tian, Lin Zhang, Taoyang Chen, et al.

    Hepatocellular carcinoma is highly chemoresistant, and ATP-binding cassette subfamily G member 2 (ABCG2) is thought to play a critical role in this drug resistance. The present study aims to develop effective therapeutic strategies to decrease ABCG2 expression level and to surmount drug resistance in hepatocellular carcinoma chemotherapy. First, we verified a positive correlation between the ABCG2 protein level and the drug resistance of hepatocellular carcinoma cell lines. ABCG2 was preferentially expressed in highly chemoresistant hepatocellular carcinoma cancer stem cells (CSC) enriched with CD133. In addition, ABCG2 was N-linked glycosylated in hepatocellular carcinoma cells, and this modification was involved in sustaining its protein stability. The N-linked glycosylation (NLG) inhibitor tunicamycin dramatically reduced ABCG2 expression, altered its subcellular localization, and reversed its drug efflux effect in multiple hepatocellular carcinoma cell lines. Furthermore, tunicamycin reduced the expression levels of several CSC markers and suppressed the tumorigenicity of CD133+ CSCs. Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr. The combination therapy more effectively suppressed tumor growth in xenograft mice than did single-agent therapy with either drug. Finally, the CDDP treatment combined with UDP-GlcNAc-dolichol-phosphate N-acetylglucosamine-1 phosphate transferase (DPAGT1) knockdown recapitulated the effect observed when CDDP was used in combination with tunicamycin. In summary, our results suggest that tunicamycin may reverse the drug resistance and improve the efficacy of combination treatments for hepatocellular carcinomas by targeting the DPAGT1/Akt/ABCG2 pathway. Mol Cancer Ther; 12(12); 2874–84. ©2013 AACR.

  • Open Access

    Data from A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

    by Qingqing Zhou, Wei Tian, Zhiyuan Jiang, Tingting Huang, Chao Ge, Tengfei Liu, Fangyu Zhao, Taoyang Chen, Ying Cui, Hong Li, et al.

    AKR1C3 is an enzyme belonging to the aldo-ketoreductase family, the members of which catalyze redox transformations involved in biosynthesis, intermediary metabolism, and detoxification. AKR1C3 plays an important role in tumor progression and metastasis, however, little is known about the function and the molecular mechanism underlying the role of AKR1C3 in hepatocellular carcinoma (HCC). In this study, we report that AKR1C3 is significantly upregulated in HCC and that increased AKR1C3 is associated with poor survival. AKR1C3 positively regulated HCC cell proliferation and metastasis in vitro and in vivo. AKR1C3 promoted tumor proliferation and metastasis by activating NF-κB signaling. Furthermore, AKR1C3 regulated NF-κB activity by modulating TRAF6 and inducing its autoubiquitination in HCC cells. Activation of NF-κB released proinflammatory factors that facilitated the phosphorylation of STAT3 and increased tumor cell proliferation and invasion. Gain- and loss-of-function experiments showed that AKR1C3 promoted tumor proliferation and invasion via the IL6/STAT3 pathway. STAT3 also directly bound the AKR1C3 promoter and increased transcription of AKR1C3, thereby establishing a positive regulatory feedback loop. Treatment with the AKR1C3 inhibitors indocin and medroxyprogesterone acetate inhibited tumor growth and invasion and promoted apoptosis in HCC cells. Collectively, these results indicate that a AKR1C3/NF-κB/STAT3 signaling loop results in HCC cell proliferation and metastasis and could be a promising therapeutic target in HCC.Significance:These findings elucidate a novel AKR1C3-driven signaling loop that regulates proliferation and metastasis in HCC, providing potential prognostic and therapeutic targets in this disease.

  • Open Access

    Data from MYC Regulates the HIF2α Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells

    by Bikul Das, Bidisha Pal, Rashmi Bhuyan, Hong Li, Anupam Sarma, Sukanya Gayan, Joyeeta Talukdar, Sorra Sandhya, Seema Bhuyan, Gayatri Gogoi, et al.

    Cancer stem cells (CSC) maintain both undifferentiated self-renewing CSCs and differentiated, non-self-renewing non-CSCs through cellular division. However, molecular mechanisms that maintain self-renewal in CSCs versus non-CSCs are not yet clear. Here, we report that in a transgenic mouse model of MYC-induced T-cell leukemia, MYC, maintains self-renewal in Sca1+ CSCs versus Sca-1− non-CSCs. MYC preferentially bound to the promoter and activated hypoxia-inducible factor-2α (HIF2α) in Sca-1+ cells only. Furthermore, the reprogramming factors, Nanog and Sox2, facilitated MYC regulation of HIF2α in Sca-1+ versus Sca-1− cells. Reduced expression of HIF2α inhibited the self-renewal of Sca-1+ cells; this effect was blocked through suppression of ROS by N-acetyl cysteine or the knockdown of p53, Nanog, or Sox2. Similar results were seen in ABCG2+ CSCs versus ABCG2− non-CSCs from primary human T-cell lymphoma. Thus, MYC maintains self-renewal exclusively in CSCs by selectively binding to the promoter and activating the HIF2α stemness pathway. Identification of this stemness pathway as a unique CSC determinant may have significant therapeutic implications.Significance:These findings show that the HIF2α stemness pathway maintains leukemic stem cells downstream of MYC in human and mouse T-cell leukemias.

  • Open Access

    Data from ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

    by Lili Zhang, Qi Huo, Chao Ge, Fangyu Zhao, Qingqing Zhou, Xiaoxia Chen, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, et al.

    Zinc finger protein 143 (ZNF143) belongs to the zinc finger protein family and possesses transcription factor activity by binding sequence-specific DNA. The exact biological role of ZNF143 in hepatocellular carcinoma (HCC) has not been investigated. Here we report that ZNF143 is overexpressed in HCC tissues and its overexpression correlates with poor prognosis. Gain- and loss-of-function experiments showed that ZNF143 promoted HCC cell proliferation, colony formation, and tumor growth in vitro and in vivo. ZNF143 accelerated HCC cell-cycle progression by activating cell division cycle 6 (CDC6). Mechanistically, ZNF143 promoted expression of CDC6 by directly activating transcription of histone demethylase mineral dust–induced gene (MDIG), which in turn reduced H3K9me3 enrichment in the CDC6 promoter region. Consistently, ZNF143 expression correlated significantly with MDIG and CDC6 expression in HCC. Collectively, we propose a model for a ZNF143–MDIG–CDC6 oncoprotein axis that provides novel insight into ZNF143, which may serve as a therapeutic target in HCC.Significance:These findings describe the mechanism by which ZNF143 promotes HCC proliferation and provide important clues for exploring new targets and strategies for clinical treatment of human liver cancer.

  • Open Access

    Supplementary Data from ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

    by Lili Zhang, Qi Huo, Chao Ge, Fangyu Zhao, Qingqing Zhou, Xiaoxia Chen, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, et al.

  • Open Access

    Supplementary Data from ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

    by Lili Zhang, Qi Huo, Chao Ge, Fangyu Zhao, Qingqing Zhou, Xiaoxia Chen, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, et al.

    Supplementary Tables includes 4 supplementary tables. Supplementary table 1-3 shows primers and target sequences of siRNA/ shRNA used in this study. Supplementary table 4 shows upregulated or downregulated genes both in MHCC-97H and Huh7 cells after MDIG knockdown.

  • Open Access

    Supplementary Data from ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

    by Lili Zhang, Qi Huo, Chao Ge, Fangyu Zhao, Qingqing Zhou, Xiaoxia Chen, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, et al.

    Supplementary Tables includes 4 supplementary tables. Supplementary table 1-3 shows primers and target sequences of siRNA/ shRNA used in this study. Supplementary table 4 shows upregulated or downregulated genes both in MHCC-97H and Huh7 cells after MDIG knockdown.

  • Open Access

    Supplementary Data from ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

    by Lili Zhang, Qi Huo, Chao Ge, Fangyu Zhao, Qingqing Zhou, Xiaoxia Chen, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, et al.

    Supplementary Figures includes 8 supplementary figures and Legends. Supplementary Figure 1 shows the expression of ZNF143 in different cancers in HCCDB database. Supplementary Figure 2 mainly shows the relationship between ZNF143 and cell cycle transition in HCC cells. Supplementary Figure 3 shows the role of CDC6 in HCC cells. Supplementary Figure 4 mainly shows the enrichment of H3K4me3 or H3K27me3 in different promoter regions of CDC6 after overexpressing ZNF143. Supplementary Figure 5 shows the relationship between MDIG and cell cycle transition in HCC cells. Supplementary Figure 6 shows the role of CBX3, CBX5 on mediating the recruitment MDIG to CDC6 promoter. Supplementary Figure 7 shows MDIG is required for ZNF143 mediated HCC cell proliferation. Supplementary Figure 8 mainly shows the clinical significance of MDIG and CDC6 in HCC.

  • Open Access

    Supplementary Data from A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

    by Qingqing Zhou, Wei Tian, Zhiyuan Jiang, Tingting Huang, Chao Ge, Tengfei Liu, Fangyu Zhao, Taoyang Chen, Ying Cui, Hong Li, et al.

    Supplementary Data, including Sup. Tables 1-5 and Sup. Figures 1-30.